Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its USA approved manufacturer for Retatrutide fiscal third-quarter results later this week. Market watchers are anticipating strong performance driven by the continued success of Lilly's blockbuster drugs, particularly the diabetes franchise. Ho